99 results on '"Mok, Tony"'
Search Results
2. A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer
3. A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma
4. Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer
5. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
6. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
7. Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma
8. Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe
9. Single-Port Video-Assisted Thoracoscopic Major Lung Resections: Experience with 150 Consecutive Cases
10. Scientific Advances in Lung Cancer 2015
11. Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations
12. First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non–Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study
13. First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
14. First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer: The ASPIRATION Study
15. Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non–Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
16. Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor
17. Antineoplastic effects of 15(S)-hydroxyeicosatetraenoic acid and 13-S-hydroxyoctadecadienoic acid in non–small cell lung cancer
18. Novel targeted agents for the treatment of lung cancer in China
19. EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey
20. First-Line Crizotinib in ALK-Positive Lung Cancer
21. Supplement to: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
22. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
23. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
24. Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
25. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
26. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
27. LUNG CANCER: Dropping bars or rising hoops—phase III outcomes of NSCLC
28. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance
29. A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015)
30. Treatment of Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
31. Mirror Mirror on the Wall, Who Is the Fairest of Them All
32. Thromboxane A2 receptor α promotes tumor growth through an autoregulatory feedback pathway
33. Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant
34. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients
35. Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
36. Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012
37. Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer
38. Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China
39. Non-small cell lung cancer: One size doesnʼt fit all
40. A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma
41. Smoking History as a Predictive Factor of Treatment Response in Advanced Non–Small-Cell Lung Cancer: A Systematic Review
42. Clinical Outcomes with Erlotinib in Patients with Epidermal Growth Factor Receptor Mutation
43. Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
44. Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma
45. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma
46. Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer
47. Clinical Outcomes with Erlotinib in Patients with Epidermal Growth Factor Receptor Mutation
48. Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells
49. Personalized medicine in lung cancer: what we need to know
50. Ethnic Differences in Survival Outcome in Patients with Advanced Stage Non-small Cell Lung Cancer: Results of a Meta-Analysis of Randomized Controlled Trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.